Neurocrine Biosciences (NBIX) Misses Q4 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Neurocrine Bio. (NBIX) PT Raised to $100 at Oppenheimer
February 14, 2018 6:21 AM ESTOppenheimer raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $100.00 (from $95.00) while maintaining a Outperform rating following Q4 results.
Analyst Jay Olson commented, "NBIX shares have outperformed YTD (+8% vs. NBI +1% and S&P 500 flat), largely driven by impressive 4Q17 sales of... More
